Randomized trial reveals lack of efficacy for L-dopa compared to nafoxidine in postmenopausal advanced breast cancer, indicating L-dopa does not induce tumor remission.
L-Dopa lowers plasma prolactin levels, and there have been reports that patients with advanced breast cancer have been successfully treated with L-dopa. To test the potential value of L-dopa in this disease a randomized clinical trial of L-dopa and nafoxidine (as the reference compound) was conducted in postmenopausal women with advanced breast cancer. Objective remissions were obtained in sever out of 36 patients (19%) treated with nafoxidine but in none out of 40 patients treated with L-dopa. L-Dopa in the dose schedule used seems to be ineffective in advanced breast cancer.
No takes yet. Share an insight, caveat, or question.
Engelsman et al. (1975) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: